Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical is making strategic moves to gain control over a target company through its subsidiary, Beijing Runkang, by acquiring a 29.99% equity interest. Additionally, another subsidiary, Shuangrun Zhengan, plans a voluntary partial offer to further increase Sino Biopharmaceutical’s stake, potentially raising its total holding to 55%. These steps could strengthen the company’s position in the market, drawing attention from investors interested in equity acquisitions and market control.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
